
Brian Baker
About Brian Baker
Brian D. Baker is President, Chief Executive Officer, Chief Financial Officer, and a Director of Dynatronics. He is 59, a director since 2023, and holds a B.A. in business from the University of Phoenix . He became CEO effective October 1, 2023, President in May 2023, and CFO in May 2025 . Prior roles include VP Global Operations at SeaSpine and VP Operations at Integra’s SeaSpine business . Pay-versus-performance disclosures show cumulative TSR value of $24.60 in 2023 dropping to $2.70 in 2025 and net losses of ($4,973k), ($2,698k), and ($10,902k) for 2023–2025, respectively, during a turnaround period .
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Dynatronics | President, Therapy Products | Feb 2018 | Brought operating leadership into therapy products segment |
| Dynatronics | Chief Operating Officer | May 2019 – Aug 2019 | Promoted to CEO; operations leadership |
| Dynatronics | Chief Executive Officer | Aug 2019 – Jul 2020 | Led company; resigned due to COVID-related health issues |
| Dynatronics | Director and Consultant | Jul 2020 – Jan 2022 | Continued contributions to strategy/governance |
| Dynatronics | Chief Operating Officer | Jan 2022 – Oct 1, 2023 | Returned to operating leadership |
| Dynatronics | President | May 2023 – present | Elevated commercial focus |
| Dynatronics | Chief Executive Officer | Oct 1, 2023 – present | Current PEO |
| Dynatronics | Chief Financial Officer | May 2025 – present | Added PFO responsibilities |
External Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| SeaSpine Holdings | VP, Global Operations | Jul 2015 – Jan 2018 | Supply chain/ops leadership in medtech |
| Integra LifeSciences (SeaSpine business) | VP, Operations | Mar 2015 – Jul 2015 | Ops leadership during transition |
| Independent | Industry Consultant | Nov 2013 – Mar 2015 | M&A advisory and process optimization |
Fixed Compensation
| Year | Base Salary ($) | Bonus ($) | Stock Awards ($) | All Other Comp ($) | Notes |
|---|---|---|---|---|---|
| 2024 | 248,582 | 11,290 | 9,284 | 13,123 | Employee director; no separate director pay |
| 2025 | 200,092 | — | — | 13,302 | Base rate cut to $150,000 effective 3/24/2025 |
Performance Compensation
Incentive program and awards
- CD&A indicates executive pay includes base salary and equity; bonuses are determined by performance goals, but specific metrics/weights are not disclosed .
- Employment Agreement terms: eligibility for annual RSUs valued at $75,000, vesting 50% on grant and 50% at first anniversary; initial contemplated grants: 50,000 RSUs (25% annually over 4 years) and 15,000 stock options (market strike) considered at the next Compensation Committee meeting .
- FY2025: Mr. Baker received no equity grants .
| Award/Metric | Target/Grant | Vesting | Actual/Payout | Status/Notes |
|---|---|---|---|---|
| Annual RSU eligibility | $75,000 RSUs per year | 50% on grant; 50% at 1-year | No FY2025 grant | From Employment Agreement; no 2025 awards |
| Initial RSU (contemplated) | 50,000 RSUs | 25% annually over 4 years | N/A | To be considered by committee per 8-K |
| Initial Options (contemplated) | 15,000 options | Service-vest per award | N/A | To be considered; market strike |
| Outstanding options (as of 6/30/25) | 18,000 exercisable | Vested | N/A | Strikes $6.95–$13.50; expire 2/26/26–8/25/27 |
| Cash bonus | Not disclosed (target) | N/A | $11,290 (2024) | No 2025 bonus disclosed |
Performance metrics table (disclosed)
| Metric | Weighting | Target | Actual | Payout | Vesting |
|---|---|---|---|---|---|
| Company/Individual goals (bonus) | Not disclosed | Not disclosed | Not disclosed | $11,290 (FY2024) | N/A |
Equity Ownership & Alignment
| Security/Class | Amount | Ownership % | Notes |
|---|---|---|---|
| Common stock (beneficial) | 364,260 | 2.3% | Based on 16,001,331 shares outstanding (10/10/2025) |
| Series A Preferred (as-converted) | 96,000 | 4.8% | As-converted voting basis; see table notes |
| Series B Preferred (as-converted) | 19,200 | — | Convertible equivalent included in total per footnote |
| Options exercisable | 18,000 | — | Vested; strikes $6.95–$13.50; expiry 2026–2027 |
| Total beneficial shares | 401,460 | 2.5% (total voting power) | Per beneficial ownership table and footnote |
- Pledging/hedging: Company prohibits pledging and hedging by executives and directors; short sales and margin also prohibited .
- Stock ownership guidelines: Not disclosed in proxy .
Employment Terms
| Term | Detail |
|---|---|
| CEO start date | October 1, 2023 |
| President start date | May 18, 2023 |
| CFO start date | May 9, 2025 |
| Base salary (initial) | $212,000 under Employment Agreement |
| Salary change | Reduced to $150,000 effective March 24, 2025 |
| Annual equity eligibility | $75,000 RSUs; 50% on grant, 50% at 1-year |
| Severance (no-cause, first 12 months) | 90 days’ base salary; 50% of Initial Awards vest (if applicable), subject to release |
| Change-in-Control (CIC) | Lump-sum 2.5x base salary within 10 business days post-CIC; no 280G gross-up (“best-net” cap); term extended through April 2028 |
| Restrictive covenants | 12-month non-compete; 2-year non-solicit; confidentiality |
| Clawback | Company adopted clawback policy compliant with Section 10D; applies to equity and cash incentives |
| At-will | Employment is at-will under the agreement |
Board Governance
- Board service: Director since 2023; not independent due to executive role .
- Leadership: Independent Chair (Erin S. Enright); roles of Chair and CEO are separated .
- Committees (FY2025): Baker is not on committees; Audit: Holtz (Chair), Enright, Hulett; Nominating, Governance and Compensation (NGC): Enright (Chair), Ward, Hulett .
- Meetings: Board met 5 times in FY2025; each director attended ≥75%; 5 executive sessions of independent directors .
- Director compensation: Employee directors receive no additional pay for board service .
Performance & Track Record
Pay vs Performance context (proxy)
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Value of $100 investment (TSR) | $24.60 | $8.69 | $2.70 |
| Net Income (Loss) ($000s) | (4,973) | (2,698) | (10,902) |
Company financials across tenure
| Metric (USD) | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|
| Revenues | $44,338,490* | $40,609,372* | $32,533,965* | $27,393,163* |
| EBITDA | ($3,521,143)* | ($3,502,827)* | ($969,342)* | ($1,347,997)* |
Values retrieved from S&P Global.*
Compensation Structure Analysis
- Mix and metrics: Program is primarily base salary plus limited equity; significant portion of any bonus is performance-based, but specific financial/operational metrics and weights are not disclosed—limiting pay-for-performance transparency .
- Equity design: Annual RSU eligibility ($75k) is service-vested (50/50); initial contemplated RSUs/options featured multi-year vesting; FY2025 included no new equity grants to Baker, reducing near-term vesting overhang .
- Cost actions: CEO base reduced to $150,000 effective March 24, 2025, signaling cost discipline/liquidity preservation .
- CIC economics: 2.5x base salary, immediate lump sum, no tax gross-up (best-net), through April 2028—meaningful protection that could influence transaction dynamics .
- Clawback, hedging/pledging bans: Strengthens alignment and risk controls relative to shareholder interests .
Risk Indicators & Red Flags
- Dual-role concentration: CEO concurrently serving as CFO (since May 2025) concentrates financial control; mitigated by independent Chair and independent Audit Committee with financial experts .
- Limited metric disclosure: Lack of disclosed incentive metrics/targets reduces visibility into pay-for-performance rigor .
- CIC payout leverage: 2.5x base (no bonus multiple) is significant for a micro-cap; no 280G gross-up (positive governance) .
- Insider trading controls: Prohibitions on pledging, hedging, and short sales reduce misalignment risk .
Say-on-Pay & Compensation Committee Practices
- Say-on-Pay frequency: Board recommends triennial “Say-When-on-Pay” votes to better align with multi-year equity vesting .
- Consultant usage: No compensation consultant engaged in FY2025 .
Equity Vesting & Insider Selling Pressure
- As of June 30, 2025, Baker held 18,000 fully vested options (strikes $6.95–$13.50, expiring 2026–2027) and no unvested stock awards—implying limited automatic vest-driven selling pressure in the near term .
- FY2025: no equity grants to Baker, further reducing near-term vesting-related supply .
Employment & Contracts – Additional Details
- Severance (first 12 months): 90 days’ salary plus 50% vesting of Initial Awards (if applicable), subject to release .
- Non-compete/non-solicit: 12-month non-compete; 2-year non-solicit; post-termination confidentiality preserved .
- Indemnification and D&O coverage provided .
Investment Implications
- Alignment: Baker owns ~2.5% of total voting power (including preferred as-converted and options), with bans on pledging/hedging—supportive of alignment, though the program’s disclosure lacks explicit financial performance targets .
- Retention and incentives: No FY2025 equity grant and a temporary salary reduction suggest near-term focus on cash preservation; multi-year vesting design (when used) supports retention, while CIC protection (2.5x base) is sizable for a micro-cap and could influence change-of-control negotiations .
- Governance checks: Independent Chair and financially expert Audit Committee provide oversight amid CEO/CFO dual role, but the concentration of roles elevates key-person and control risks .
- Performance baseline: TSR deterioration and continued net losses underscore execution risk and the necessity of operational improvements; absence of disclosed incentive metrics limits visibility into whether incentives directly target revenue growth, margin expansion, or TSR recovery .
Citations:
[6:x] refers to the October 2, 2023 8-K and its exhibits.
[26:x] refers to the 2025 DEF 14A proxy statement.